Search Results

December 6, 2020

New Data Demonstrate Long-Term Benefit of IMBRUVICA® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia

IMBRUVICA® pooled clinical trial analyses presented at ASH demonstrate sustained efficacy and safety in patients with historically poor outcomes Data from real-world evidence studies featured as oral presentations highlight the benefit of IMBRUVICA®-based therapies in the first-line setting

Innovative Medicine

December 5, 2020

Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma

Data presented at ASH 2020 for first-in-class talquetamab support recommended Phase 2 dose with subcutaneous formulation

Innovative Medicine

December 5, 2020

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia

New data from the double-blind, placebo-controlled, randomized phase of the Phase 2 CAPTIVATE study presented at ASH 2020 showed that 95 percent of patients with undetectable minimal residual disease randomized to discontinue active treatment after twelve cycles of treatment with IMBRUVICA® plus venetoclax were disease-free and alive, supporting a fixed duration treatment approach

Innovative Medicine

December 3, 2020

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Expanded Access Program Established for Patients in the U.S. Who May Benefit from Investigational Therapy While Application is Under Review

Innovative Medicine

December 2, 2020

Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration

Acquisition significantly expands Janssen’s eye disease portfolio and strengthens its gene therapy capabilities Late-stage AMD affects millions of people with no effective treatments currently available

Innovative Medicine

November 13, 2020

Late-Breaking 12-Month Data of Investigational RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa

One-year findings support advancement into Phase 3 and include significant functional vision improvements observed in the time taken to walk through a vision-guided mobility maze at nine months

Innovative Medicine

November 9, 2020

New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020

Data includes several analyses from the landmark VOYAGER PAD trial, including findings in high-risk patients with critical limb ischemia (CLI) after lower-extremity revascularization (LER) XARELTO® has the potential to be the first anticoagulant in 20 years to show a benefit in patients with PAD after LER[i] The comprehensive PAD program within EXPLORER continues to generate new findings that may shift the way symptomatic and chronic patients are managed

Innovative Medicine

November 5, 2020

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio

- New cilta-cel (BCMA CAR-T) data from the Phase 1b/2 CARTITUDE-1 study in relapsed or refractory multiple myeloma - New DARZALEX® (daratumumab) and DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) data across early lines of treatment in multiple myeloma and in amyloid light-chain (AL) amyloidosis - New data for bispecific antibodies talquetamab and teclistamab in relapsed or refractory multiple myeloma - New data investigating IMBRUVICA® (ibrutinib) as time-limited therapy in chronic lymphocytic leukemia (CLL) and long-term results in CLL, mantle cell lymphoma (MCL) and Waldenström’s Macroglobulinemia (WM)

Innovative Medicine

October 26, 2020

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease

Application seeks approval of XARELTO® plus aspirin to reduce the risk of major thrombotic vascular events in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) XARELTO® is currently approved to reduce the risk of major cardiovascular events, like heart attack and stroke, in people with chronic PAD An estimated 20 million Americans are living with PAD, a disease often underdiagnosed and undertreated

Corporate

October 8, 2020

Champions of Science: Breaking the Stigma of Mental Illness

Join us for a special virtual event celebrating the champions who are helping to eliminate stigma and improve mental healthcare in communities around the world

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine